You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023920014
Dec 202364010
Jan 20244702
Feb 20245003
Mar 20244005
Apr 20247609
May 20242803
Jun 20243802
Jul 20242406
Aug 20242403
Sep 20243202
Oct 20242404
Nov 20242406
Dec 20242407
Jan 20253204
Feb 20251204
Mar 20250011
Apr 2025004
May 2025004
Jun 20250011
Total14590114